Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

Study limitation reported by the research below: “Atrial fibrillation/flutter patients were only allowed in phase 2a, creating heterogeneity between phases.”